Coffee derived diterpene esters fatty acids and caffaldehydes as potential modulators of intestinal alpha glucosidase activity

α-Glucosidase inhibitors are widely used for the management of postprandial hyperglycemia; however, conventional carbohydrate-mimetic inhibitors, such as acarbose, are frequently associated with gastrointestinal adverse effects resulting from potent catalytic-site inhibition. Emerging evidence suggests that coffee-derived diterpene esters, caffaldehydes and related fatty acid conjugates represent a distinct class of lipid-centric α-glucosidase modulators with mechanisms that differ fundamentally from classical active-site inhibitors. This review integrates current knowledge from structural chemistry, structure-activity relationships (SAR), membrane biology and computational studies to examine how esterification with saturated and monounsaturated fatty acids, including palmitic, stearic, arachidic, margaricand nonadecanoic acids, influences physicochemical properties and enzyme interactions. Available computational and indirect biochemical evidence indicates that these amphiphilic compounds may preferentially interact with peripheral or membrane-proximal regions of α-glucosidase, potentially altering substrate recognition and enzyme dynamics through non-competitive mechanisms rather than direct catalytic-site occupancy. Fatty acid chain length, saturation and ester composition further influence lipophilicity, binding behavior, esterase-mediated hydrolysis and biological activity, while oxidized derivatives such as caffaldehydes may enhance interaction stability through reversible covalent chemistry. Although these findings support the potential of coffee-derived diterpene esters as nutraceutical candidates for improving postprandial glycemic control, the proposed mechanisms remain largely hypothesis-driven and require validation through structural, biochemical, pharmacokinetic and in vivo studies. Furthermore, intact diterpene esters primarily exert localized intestinal effects before esterase-mediated hydrolysis releases free cafestol and kahweol, which become systemically absorbed. Given the recognized cholesterol-elevating effects of cafestol, future therapeutic development should carefully balance efficacy with cardiovascular safety through optimized formulation, controlled dosage and comprehensive clinical evaluation.